Market Overview

Coca-Cola Enters Into Long-Term Strategic Partnership With Monster

Share:

Coca-Cola Company (NYSE: KO) and Monster Beverage (NASDAQ: MNST) announced a long-term strategic partnership after Thursday's market close.

As part of the deal, Coca-Cola will purchase a 16.7 percent equity stake in Monster and will make Monster its sole play in the energy drink space.

Coca-Cola will have two directors on Monster's Board of Directors and expects to account for the investment under the equity accounting method.

"The Coca-Cola Company continues to identify innovative approaches to partnerships that enable us to stay at the forefront of consumer trends in the beverage industry," said Muhtar Kent, chairman and chief executive officer of The Coca-Cola Company. "Our equity investment in Monster is a capital efficient way to bolster our participation in the fast-growing and attractive global energy drinks category."

Rodney C. Sacks, chairman and CEO of Monster, commented, “We gain enhanced access to The Coca-Cola Company's distribution system, the most powerful and extensive system in the world. At the same time, we become The Coca-Cola Company's exclusive energy play, with a robust portfolio led by our Monster Energy line and The Coca-Cola Company's energy brands."

Posted-In: Muhtar Kent Rodney C. SacksM&A News

 

Related Articles (KO + MNST)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Carl Icahn 13F Filing Shows $229M Stake In Gannett

Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine